Galapagos shares drop 6% as Deutsche Bank cuts rating on strategy concerns

Published 06/08/2025, 12:26
© Reuters

Investing.com -- Shares of Galapagos (AS:GLPG) fell 6% on Wednesday after analysts at Deutsche Bank (ETR:DBKGn) downgraded the stock to “sell” from “hold,” citing growing uncertainty around the company’s direction and future strategy. The price target was lowered to €19 from €22. 

The downgrade follows the biotech company’s second-quarter update and reflects concerns over the removal of cash guidance, ambiguity in corporate structure, and risks tied to ongoing business development efforts and cell therapy programs.

Galapagos has undergone a series of major strategic changes over the past year. In 2023, the company divested Jyseleca, its JAK inhibitor for inflammatory diseases, and shifted focus to oncology, specifically CAR-T cell therapies. 

At the time, Galapagos said it would not be pursuing a leading position in the CAR-T space.

In January, Galapagos announced a further shift with plans to split the company and launch SpinCo, a separate entity aimed at acquiring and licensing assets in immunology, oncology, and virology. 

Deutsche Bank analysts described the move as high-risk and not suited for risk-averse investors.

Deutsche Bank analysts said the lack of clarity surrounding the company’s structure and capital deployment strategy now outweighs the potential upside, prompting the downgrade.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.